In this study, we present a case of colorectal cancer that demonstrated resistance to the encorafenib and cetuximab regimen, attributed to the presence of a KRAS mutation in addition to BRAF. The information obtained from both companion diagnosis and CGP testing proved beneficial for selecting the appropriate drug in the later stages of treatment. This evidence concerns the gene BRAF and colorectal cancer.